A new COVID-19 variant, BA.3.2—nicknamed “Cicada”—has re-entered global focus as it spreads across the United States and more than 20 countries. First detected in South Africa in November 2024, the variant is being closely monitored due to its unusually high number of mutations and potential to partially evade immunity from vaccines or prior infections.
Despite these concerns, global health agencies stress that there is no evidence of increased severity or hospitalisation so far. With detections rising through traveller screenings, clinical samples and wastewater surveillance, BA.3.2 highlights how the virus continues to evolve, making vigilance more important than panic.
BA.3.2 ‘Cicada’ Variant: Key Facts, Global Spread, Symptoms and Vaccine Impact
- Highly mutated Omicron subvariant with 70–75 mutations
- First identified in South Africa (November 2024)
- Classified as a Variant Under Monitoring (WHO, December 2025)
- Detected in 23+ countries and 25–29 US states + Puerto Rico
- Found through travellers, clinical samples, airplane and community wastewater (132+ sites)
- Shows partial immune escape potential
- Symptoms largely similar to Omicron, but severe sore throat stands out
- No increase in hospitalisation, severity or death rates
- Vaccines may be less effective against infection but still protect against severe disease
- Not a dominant strain; variants like XFG and NB.1.8.1 continue to lead
What Is the BA.3.2 ‘Cicada’ Variant?
BA.3.2 is a genetically distinct sublineage of the Omicron variant of SARS-CoV-2. Unlike the JN.1-related variants that have dominated infections in recent years, BA.3.2 comes from an older BA.3 lineage that had largely disappeared after early 2022. Scientists describe it as a “long-branch descendant,” meaning it evolved quietly over time before re-emerging.
Two sublineages—BA.3.2.1 and BA.3.2.2—have already been identified, showing that the virus continues to evolve. The nickname “Cicada” reflects this unusual pattern, as the variant remained “underground” before appearing more prominently in 2025.
What makes BA.3.2 particularly notable is its 70–75 mutations in the spike protein, the part of the virus responsible for entering human cells. This raises concerns about how it spreads and how the immune system responds.
Why Experts Are Watching BA.3.2 Closely
The attention around BA.3.2 is driven by three key factors. First, its high mutation load makes it one of the most heavily mutated variants identified so far. Second, early studies suggest it may have the ability to partially evade immunity built from previous infections or vaccinations. Third, its global spread across multiple continents indicates that it is actively circulating.
However, experts repeatedly stress that being under monitoring does not mean it is a major threat. So far, real-world data has not shown any increase in severity.
Global Spread and US Situation
BA.3.2 has now been detected across more than 20 countries, including the United States, United Kingdom, Japan, Kenya, Australia and several European nations. In parts of Europe—particularly Denmark, Germany and the Netherlands—the variant has accounted for up to 30% of cases during certain periods.
In the United States, the variant has been identified in 25 to 29 states and Puerto Rico. It has been detected through multiple surveillance systems, including traveller screenings, clinical testing and wastewater monitoring. Notably, it has been found in 132 wastewater samples across more than 25 states, as well as in airplane wastewater samples, indicating broader and possibly undercounted spread.
Current Situation Snapshot
| Indicator | Data |
| Countries affected | 23+ |
| US states affected | 25–29 + Puerto Rico |
| US prevalence | ~0.55% |
| Wastewater detection | ~3.7% |
| Europe share (select regions) | Up to 30% |
| Dominant variant (US) | XFG (~53%) |
Although BA.3.2 has been detected in half of the United States, it is still not the dominant strain.
How the Cicada Variant Spreads
The BA.3.2 variant spreads in the same way as earlier COVID-19 strains, primarily through respiratory droplets and aerosols when an infected person coughs, sneezes or speaks. Transmission is more likely during close, prolonged contact, especially in indoor settings.
In less common cases, the virus can spread through contaminated surfaces, if a person touches them and then touches their face.
While its mutations may help it spread among people with existing immunity, some laboratory findings suggest that certain changes could also lead to reduced binding efficiency to human cells, meaning it may not always be more infectious in real-world conditions.
Symptoms of BA.3.2: What to Watch For
The symptoms associated with BA.3.2 are largely similar to those seen in other Omicron variants, but doctors have observed one key difference—a more intense or severe sore throat.
Common Symptoms
- Fever or chills
- Dry cough
- Fatigue
- Headache
- Body aches
- Runny or blocked nose
- Congestion
Additional Symptoms
- Loss of taste or smell
- Shortness of breath
- Sneezing
Gastrointestinal Symptoms
- Nausea
- Vomiting
- Diarrhoea
Less Common Observations
- Night sweats
- Skin rashes
- “Razor blade throat” sensation
In most cases, symptoms remain mild and resolve with supportive care, especially in vaccinated individuals.
When to Seek Emergency Medical Help
While most infections are mild, immediate medical attention is required if symptoms become severe.
- Difficulty breathing or inability to speak properly
- Oxygen levels below 94%
- Persistent high fever (above 102°F for more than 3 days)
- Chest pain or pressure
- Confusion or unusual behaviour
- Blue or pale lips or skin
- Severe dehydration or inability to retain fluids
Children may show warning signs such as reduced urination, unusual drowsiness, irritability or breathing distress.
Does BA.3.2 Cause More Severe Disease?
Current evidence from global health agencies and researchers indicates that BA.3.2 does not cause more severe illness than earlier variants.
There has been:
- No significant rise in hospitalisations
- No increase in death rates
- Symptoms largely limited to mild respiratory illness
Experts note that although the variant appears concerning due to its mutation profile, it has not translated into more serious outcomes in real-world data.
What Experts Say About the Cicada Variant
Health experts across institutions have offered a consistent message. Virologist Andrew Pekosz has noted that while the variant is evolving, it has not shown signs of being an immediate threat. Robert H. Hopkins Jr. has highlighted that although vaccine effectiveness against infection may be reduced, severity does not appear higher.
Angela Rasmussen has explained that viral evolution depends on how often the virus replicates, while Dana Mazo has pointed out that some mutations may even reduce how effectively the virus binds to human cells. García-Sastre has also confirmed that there is no evidence of increased severity so far.
Vaccine Effectiveness and Immunity
One of the key concerns surrounding BA.3.2 is whether current vaccines remain effective. Since existing vaccines are designed around earlier lineages such as JN.1, the genetic differences in BA.3.2 raise questions about protection.
Studies suggest that while vaccines may be less effective at preventing infection, they continue to offer strong protection against:
- Severe illness
- Hospitalisation
- Death
Booster doses remain important, and experts indicate that vaccines can be updated if needed to better match emerging variants.
Could BA.3.2 Trigger a New COVID Wave?
At present, BA.3.2 is increasing gradually but has not caused a major surge in cases anywhere in the world. It has also not demonstrated a clear growth advantage over other circulating variants.
While some experts say it could potentially contribute to a future or seasonal surge, others emphasise that it may remain a minor variant. The situation remains uncertain and depends on how the virus evolves.
US Vulnerability and Ongoing Risk
Experts have warned that lower vaccination rates and reduced public health measures could leave populations more vulnerable to emerging variants.
Although overall COVID trends have declined, the virus has not disappeared. In the United States alone, over 3,600 COVID-related deaths have been reported this year, indicating that the disease still poses a risk.
What About India?
As of now, there is no evidence of widespread BA.3.2 circulation in India. However, health authorities are closely monitoring the situation due to the variant’s global spread.
With international travel continuing, experts believe that vigilance and surveillance remain essential. At present, there are no signs of major disruption or restrictions.
Precautions That Still Work
Despite new variants, the most effective protection strategies remain unchanged. Staying updated with vaccinations and booster doses continues to be important, especially for vulnerable populations.
Wearing well-fitted masks such as N95 or KN95 in crowded indoor spaces can significantly reduce risk. Maintaining good ventilation indoors, practising regular hand hygiene, and getting tested when symptoms appear are also key steps. People who feel unwell should stay home to prevent further spread.
Spiritual Insight: Understanding Life, Suffering and True Protection Through the Knowledge of Saint Rampal Ji Maharaj Ji
While science continues to study evolving viruses like COVID-19, the deeper question many people ask is about fear, uncertainty and the purpose of human life. According to the teachings of Saint Rampal Ji Maharaj, physical challenges such as diseases are part of the natural cycle of life, but true peace and protection come from spiritual awareness and correct knowledge of God.
He explains that human life is precious and meant for attaining liberation, not just dealing with temporary worldly problems. His teachings emphasise that by following true spiritual practices, chanting the correct mantras and living a disciplined life, a person can rise above fear, stress and suffering.
In times when new diseases or uncertainties arise, spiritual understanding helps individuals remain mentally strong and balanced. Saint Rampal Ji Maharaj Ji’s knowledge encourages people to focus on both physical precautions and inner spiritual growth.
His message highlights that while science protects the body, true devotion and right knowledge protect the soul, guiding individuals toward lasting peace and a fearless life.
Why Vigilance Matters More Than Panic
The BA.3.2 ‘Cicada’ variant is a reminder that COVID-19 continues to evolve, but it does not signal a return to the early days of the pandemic. Despite its high mutation count and ability to partially evade immunity, there is no evidence so far of increased severity or widespread disruption. Health systems are better equipped, vaccines continue to protect against serious outcomes, and surveillance systems are actively tracking changes.
The focus now is on awareness and preparedness rather than fear. Staying informed, following basic precautions and relying on credible health guidance remain the most effective ways to navigate this evolving situation.
FAQs on BA.3.2 ‘Cicada’ COVID Variant
1. What is the BA.3.2 ‘Cicada’ COVID variant?
BA.3.2 is a highly mutated Omicron subvariant with 70–75 mutations, first detected in South Africa, now spreading across 20+ countries and being monitored globally.
2. What are the symptoms of the Cicada COVID variant?
Symptoms include fever, cough, fatigue, congestion, and a notably severe sore throat. Some cases also report nausea, diarrhoea, loss of taste or smell, and shortness of breath.
3. Is the BA.3.2 Cicada variant more dangerous than previous variants?
No. Current evidence shows no increase in severity, hospitalisation, or death rates. Most cases remain mild, similar to other Omicron variants.
4. Do current COVID vaccines work against the BA.3.2 variant?
Vaccines may be less effective at preventing infection but still provide strong protection against severe illness, hospitalisation, and death.
5. Where has the BA.3.2 Cicada variant been detected?
The variant has been detected in 20+ countries and 25+ US states, including through travellers, clinical samples, and wastewater surveillance systems.
